// App-Quantinova.ai

1583 : Venetoclax Resistant Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Cells Are Also Resistant to ABL Inhibitors, Which Can be Overcome By Targeting the PI3K/AKT/ mTOR Pathway

Researchers

Presenter

  • Jessica T Leonard

Principal Investigators

  • Jeffrey W. Tyner

  • Joelle Rowley

  • Marc M. Loriaux

  • Brian J. Druker

  • Bill H. Chang

Medical Centers

  • Knight Cancer Institute, Oregon Health and Science University, Portland, OR

  • Knight Cancer Institute, Department of Pathology, Oregon Health & Science University, Portland, OR

  • Knight Cancer Institute, Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR

  • Department of Cell & Developmental Biology, Oregon Health & Science University, Portland, OR

  • Howard Hughes Medical Institute, Portland, OR

  • Oregon Health and Science University, Portland, OR

  • Oregon Health & Science University, OHSU Knight Cancer Institute, Portland, OR

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • Serine/threonine-protein kinase mTOR

  • PI3K/AKT

Drug/Treatment

  • Venetoclax

  • dasatinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved